Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 8Phase 1/2 5Phase 3 4Phase EARLY_PHASE1 2Phase 4 1

Status

Recruiting 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 172Neoplasms 167Colorectal Neoplasms 154Neoplasm Metastasis 127Melanoma 119Recurrence 116Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 110Multiple Myeloma 103Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 82Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 76Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 64Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 54Sarcoma 52Uterine Cervical Neoplasms 51Myelodysplastic Syndromes 51Advanced Solid Tumors 49

Interventions

Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Castration-resistant Prostate Cancer × 1 year × Clear all
NCT05682443 2026-05-22

PRESERVE-006

OncoC4, Inc.

Phase 1/2 Active not recruiting
148 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05125016 2026-05-05

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
228 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05570994 2026-01-08

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

British Columbia Cancer Agency

Phase 1/2 Enrolling by invitation
50 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06155084 2025-12-22

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Hinova Pharmaceuticals Inc.

Phase 1/2 Recruiting
84 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07172126 2025-09-15

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Not yet recruiting
291 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡